STOCK TITAN

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Positive)
Tags

Pacira BioSciences (Nasdaq: PCRX), a leader in non-opioid pain therapies, has granted inducement awards to four new employees on December 3, 2024. The awards include:

- Stock options to purchase 19,800 shares of common stock at $16.68 per share, with a 10-year term and four-year vesting schedule

- 23,600 restricted stock units (RSUs) vesting annually in four equal installments starting December 1, 2024

The awards were approved by the Compensation Committee under Pacira's Amended and Restated 2014 Inducement Plan and comply with Nasdaq Listing Rule 5635(c)(4). Vesting is contingent upon continued employment.

Pacira BioSciences (Nasdaq: PCRX), leader nelle terapie antidolorifiche non oppiacee, ha concesso premi di incentivazione a quattro nuovi dipendenti il 3 dicembre 2024. I premi includono:

- Opzioni azionarie per acquistare 19.800 azioni ordinarie a $16,68 per azione, con un termine di 10 anni e un piano di maturazione di quattro anni

- 23.600 unità azionarie restrittive (RSU) che maturano annualmente in quattro rate uguali a partire dal 1 dicembre 2024

I premi sono stati approvati dal Comitato di Compensazione ai sensi del Piano Ampliato e Riveduto di Incentivazione 2014 di Pacira e sono conformi alla Regola di Quotazione Nasdaq 5635(c)(4). La maturazione è soggetta a un impiego continuativo.

Pacira BioSciences (Nasdaq: PCRX), líder en terapias para el dolor no opioide, ha otorgado premios de incentivo a cuatro nuevos empleados el 3 de diciembre de 2024. Los premios incluyen:

- Opciones de acciones para comprar 19,800 acciones comunes a $16.68 por acción, con un plazo de 10 años y un cronograma de adquisición de cuatro años

- 23,600 unidades de acciones restringidas (RSUs) que se adquirirán anualmente en cuatro cuotas iguales a partir del 1 de diciembre de 2024

Los premios fueron aprobados por el Comité de Compensación bajo el Plan de Incentivos Modificado y Restituido de 2014 de Pacira y cumplen con la Regla de Listado de Nasdaq 5635(c)(4). La adquisición está sujeta a la continuidad del empleo.

Pacira BioSciences (Nasdaq: PCRX)는 비오피오이드 통증 치료의 선두주자로서 2024년 12월 3일에 네 명의 새로운 직원에게 유인 수당을 지급했습니다. 수당에는 다음이 포함됩니다:

- 19,800주의 보통주를 주당 $16.68에 구매할 수 있는 주식 옵션으로, 10년의 기간과 4년의 취득 일정이 있습니다.

- 23,600 제한 주식 단위 (RSUs)는 2024년 12월 1일부터 시작하여 매년 4회 균등하게 취득됩니다.

이 수당은 Pacira의 2014년 수정 및 재정비 유인 계획에 따라 보상위원회에서 승인되었으며, Nasdaq 상장 규칙 5635(c)(4)를 준수합니다. 취득은 계속 고용에 따라 조건이 부여됩니다.

Pacira BioSciences (Nasdaq: PCRX), leader dans les thérapies pour la douleur non opioïde, a accordé des primes d'incitation à quatre nouveaux employés le 3 décembre 2024. Les primes comprennent :

- Des options d'achat d'actions pour acquérir 19 800 actions ordinaires à 16,68 $ par action, avec une durée de 10 ans et un calendrier d'acquisition de quatre ans

- 23 600 unités d'actions restreintes (RSUs) qui acquièrent de manière annuelle en quatre versements égaux à partir du 1er décembre 2024

Les primes ont été approuvées par le Comité de Rémunération dans le cadre du Plan d'Incentives modifié et révisé de 2014 de Pacira et sont conformes à la Règle d'inscription Nasdaq 5635(c)(4). L'acquisition est conditionnée à la continuité de l'emploi.

Pacira BioSciences (Nasdaq: PCRX), ein führendes Unternehmen im Bereich nicht-opioider Schmerztherapien, hat am 3. Dezember 2024 vier neuen Mitarbeitern Anreizvergütungen gewährt. Die Vergütungen umfassen:

- Aktienoptionen zum Kauf von 19.800 Aktien zu je $16,68 mit einer Laufzeit von 10 Jahren und einem vierjährigen Vesting-Zeitplan

- 23.600 eingeschränkte Aktieneinheiten (RSUs), die jährlich in vier gleichen Raten ab dem 1. Dezember 2024 fällig werden

Die Vergütungen wurden vom Vergütungsausschuss im Rahmen des geänderten und aktualisierten Anreizplans für 2014 von Pacira genehmigt und entsprechen der Nasdaq-Listing-Regel 5635(c)(4). Das Vesting ist an die Fortsetzung der Beschäftigung gebunden.

Positive
  • None.
Negative
  • None.

PARSIPPANY, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on December 3, 2024 to four new employees under Pacira’s Amended and Restated 2014 Inducement Plan as a material inducement to each employee's entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the Compensation Committee of the Board of Directors.

Four employees received stock options to purchase an aggregate of 19,800 shares of Pacira common stock and the four employees received restricted stock units for an aggregate of 23,600 shares of Pacira common stock.

The stock options have a 10-year term and a four-year vesting schedule with 25 percent of the underlying shares vesting on the first anniversary of the recipient’s first day of employment and in successive equal quarterly installments over the 36 months thereafter. The stock options have an exercise price of $16.68 per share, the closing trading price of Pacira common stock on the Nasdaq Global Select Market on the date of grant. Each restricted stock unit represents the contingent right to receive one share of Pacira common stock and the restricted stock unit awards vest annually in four equal installments beginning on the first anniversary of December 1, 2024.

Vesting of the equity awards is subject to the employee’s continued employment with Pacira. Each equity award is also subject to the terms and conditions of an award agreement.

About Pacira

Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and ioveraº®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing the development of PCRX-201, a novel locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com.

Forward-Looking Statements

Any statements in this press release about Pacira’s future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “should,” “will,” “would,” and similar expressions, constitute forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to our future outlook, our intellectual property and patent terms, our growth and future operating results and trends, our strategy, plans, objectives, expectations (financial or otherwise) and intentions, future financial results and growth potential, including our plans with respect to the repayment of our indebtedness, anticipated product portfolio, development programs, development of products, strategic alliances, plans with respect to the Non-Opioids Prevent Addiction in the Nation (“NOPAIN”) Act and other statements that are not historical facts. For this purpose, any statement that is not a statement of historical fact should be considered a forward-looking statement. We cannot assure you that our estimates, assumptions and expectations will prove to have been correct. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to, among others: the integration of our new chief executive officer; risks associated with acquisitions, such as the risk that the acquired businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the transaction will not occur; our manufacturing and supply chain, global and U.S. economic conditions (including inflation and rising interest rates), and our business, including our revenues, financial condition, cash flow and results of operations; the success of our sales and manufacturing efforts in support of the commercialization of EXPAREL, ZILRETTA and iovera°; the rate and degree of market acceptance of EXPAREL, ZILRETTA and iovera°; the size and growth of the potential markets for EXPAREL, ZILRETTA and iovera° and our ability to serve those markets; our plans to expand the use of EXPAREL, ZILRETTA and iovera° to additional indications and opportunities, and the timing and success of any related clinical trials for EXPAREL, ZILRETTA and iovera°; the commercial success of EXPAREL, ZILRETTA and iovera°; the related timing and success of U.S. Food and Drug Administration supplemental New Drug Applications and premarket notification 510(k)s; the related timing and success of European Medicines Agency Marketing Authorization Applications; our plans to evaluate, develop and pursue additional product candidates utilizing our proprietary multivesicular liposome (“pMVL”) drug delivery technology; the approval of the commercialization of our products in other jurisdictions; clinical trials in support of an existing or potential pMVL-based product; our commercialization and marketing capabilities; our ability to successfully complete capital projects; the outcome of any litigation; the ability to successfully integrate any future acquisitions into our existing business; the recoverability of our deferred tax assets; assumptions associated with contingent consideration payments; assumptions used for estimated future cash flows associated with determining the fair value of the Company; the anticipated funding or benefits of our share repurchase program; and factors discussed in the “Risk Factors” of our most recent Annual Report on Form 10-K and in other filings that we periodically make with the Securities and Exchange Commission (the “SEC”). In addition, the forward-looking statements included in this press release represent our views as of the date of this press release. Important factors could cause actual results to differ materially from those indicated or implied by forward-looking statements, and as such we anticipate that subsequent events and developments will cause our views to change. Except as required by applicable law, we undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, and readers should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.


FAQ

How many shares were granted in Pacira BioSciences (PCRX) December 2024 inducement awards?

Pacira granted stock options for 19,800 shares and 23,600 restricted stock units (RSUs) to four new employees.

What is the exercise price for PCRX stock options granted on December 3, 2024?

The stock options were granted with an exercise price of $16.68 per share, which was Pacira's closing price on Nasdaq on the grant date.

What are the vesting terms for PCRX's December 2024 inducement awards?

Stock options vest 25% after one year, then quarterly over 36 months. RSUs vest annually in four equal installments starting December 1, 2024.

Pacira BioSciences, Inc.

NASDAQ:PCRX

PCRX Rankings

PCRX Latest News

PCRX Stock Data

903.66M
45.12M
2.15%
114.62%
10.44%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
TAMPA